エンジニアリング制御放出ステロイド療法:自己組み立てマイクロ粒子の製造と分子設計
Oluwaseun D Akanbi1, Michael L Felder1, Daniel Kupor1
1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Science advances
|February 20, 2026
まとめ
素粒子ベースのステロイド薬は,肝臓の疾患と炎症に対する長期的な治療効果を提供します. この研究では,新しいステロイドマイクロ粒子が開発され,薬剤の投与を改善し,頻繁な投与の必要性を軽減しました.
科学分野:
- 医薬品科学 医薬品科学とは
- マテリアルサイエンス 材料科学
- コンピューティング・ケミストリー
背景:
- ステロイド薬 (胆塩,コルチコステロイド) は肝臓機能不全や炎症を治療するが,半減期は短い.
- 迅速なクリアランスは頻繁な投与を必要とし,治療効果と患者の服従を制限します.
- 粒子ベースの薬剤投与システムは,持続的な治療活動に不可欠です.
研究 の 目的:
- 新規のステロイドマイクロ粒子を開発し,薬剤の投与を向上させる.
- 製造方法とマイクロ粒子の形成と形態学に影響を与える要因を調査する.
- 粒子ベースのステロイド療法の臨床翻訳の可能性を探求する.
主な方法:
- ステロイド微粒子は,金属または有機酸によって促進される3つの異なるプロセスを使用して製造されます.
- 粒子の形状,サイズ,結晶性の特徴.
- 素粒子の形成における水素結合の役割を明らかにするために,粗い粒子の計算モデリング.
- 粒子の形状を調整するためにステロイドC21のサイドグループを化学的に改変する.
主要な成果:
- 製造されたステロイドマイクロ粒子は,一貫した形状,サイズ,および結晶性を示しました.
- 計算モデルにより,粒子形態学の重要な決定因子として水素結合が明らかになった.
- ステロイド粒子の形成と形態は,C21側グループの化学的改変によってうまく調整されました.
結論:
- 制御された性質を持つステロイド微粒子を製造するための新しい方法が確立されました.
- ステロイド粒子の形成を制御する分子相互作用の理解が進んでいた.
- この研究は,従来の配方に対する改善された代替品として,粒子ベースのステロイド療法薬の臨床翻訳をサポートしています.
関連する概念動画
Modified-Release Drug Delivery Systems: Rate-Programmed II
38
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
38
Modified-Release Drug Delivery Systems: Classification
47
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
47
Site-Targeted Drug Delivery Systems: Polymeric Carriers
36
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
36
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
38
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
38
Modified-Release Drug Delivery Systems: Site-Targeted
33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Intrauterine Drug Delivery Systems
34
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
34


